LONDON, ONTARIO, May 20, 2010 (MARKETWIRE via COMTEX) -- Critical Outcome Technologies Inc. (COTI) /quotes/comstock/11v!e:cot (CA:COT 0.34, +0.01, +1.49%) today announced positive results from the first phase of its HIV integrase inhibitor discovery program. These results provide novel intellectual property to the Company and further validation of the CHEMSAS(R) drug discovery technology.
